Table 2.
Demografic and clinical characteristics of the patients
| Patient ID | Sex | Age (year) | Smoker or ex-smoker | Raynaud’s phenomenon type | Previous treatments | Ulcers and/or necrosis | Infiltrated toxin units |
|---|---|---|---|---|---|---|---|
| 1 | F | 52 | No | Secondary LSS | Iloprost, nifedipine | Yes | L: 48 R: 48 |
| 2 | F | 41 | Yes | Secondary LSS | Nifedipine | No | L: 40 R: 40 |
| 3 | F | 51 | No | Secondary LSS | Nifedipine | Yes | L: 52 R: 48 |
| 4 | F | 35 | No | Secondary LSS | Nifedipine, bosentan, iloprost, pentoxifylline | Yes | L: 36 R: 40 |
| 5 | F | 41 | No | Secondary MCTD | Nifedipine | Yes | L: 32 R: 64 |
| 6 | F | 37 | No | Primary | Pentoxifylline, nifedipine | No | L: 52 R: 44 |
| 7 | F | 48 | Ex-smoker (10 years) | Secondary LSS | Nifedipine | No | L: 34 R: 36 |
| 8 | F | 46 | NA | Secondary DSS | Amlodipine | No | L: 40 R: 44 |
| 9 | F | 71 | NA | Secondary LSS | Diltiazem | No | L: 44 R: 56 |
| 10 | F | 52 | Ex-smoker (1 year) | Secondary LSS | Nifedipine | No | L: 34 R: 34 |
| 11 | F | 54 | NA | Primary | Nifedipine | No | L: 44 R: 46 |
| 12 | F | 41 | Ex-smoker (10 years) | Secondary DSS | Pentoxifylline, amlodipine | Yes | L: 50 R: 50 |
| 13 | F | 44 | NA | Secondary MCTD | Pentoxifylline, nifedipine | No | L: 46 R: 50 |
| 14 | F | 43 | NA | Secondary MCTD | Nifedipine | No | L: 40 R: 60 |
| 15 | M | 69 | NA | Secondary MCTD | Nifedipine | No | L: 50 R: 50 |
DSS: diffuse systemic scleroderma; F: female; ID: identification; L: left; LSS: limited systemic scleroderma; MCTD: mixed connective tissue disease; M: male; NA: not available; R: right